Next Article in Journal
RNA Detection in Live Bacterial Cells Using Fluorescent Protein Complementation Triggered by Interaction of Two RNA Aptamers with Two RNA-Binding Peptides
Next Article in Special Issue
Functional Consequences of GPCR Heterodimerization: GPCRs as Allosteric Modulators
Previous Article in Journal
Myocardial Opioid Receptors in Conditioning and Cytoprotection
Previous Article in Special Issue
Dual-Color Bioluminescence Analysis for Quantitatively Monitoring G-Protein-Coupled Receptor and β-Arrestin Interactions
Pharmaceuticals 2011, 4(3), 485-493; doi:10.3390/ph4030485

Neuropeptide Receptors: Novel Targets for HIV/AIDS Therapeutics

1 Department of Medicine, University of Toronto, Toronto, Ontario M5G 2M1, Canada 2 Department Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5G 2M1, Canada 3 Research & Development, Toronto Immunology Hub, Canadian Blood Services, Toronto, Ontario M5G 2M1, Canada
Received: 3 February 2011 / Revised: 4 March 2011 / Accepted: 7 March 2011 / Published: 9 March 2011
(This article belongs to the Special Issue GPCR Based Drug Discovery)
View Full-Text   |   Download PDF [236 KB, uploaded 9 March 2011]   |  


The vasoactive intestinal peptide/pituitary adenylyl cyclase-activating polypepetide (VPAC) receptors are important for many physiologic functions, including glucose homeostasis, neuroprotection, memory, gut function, modulation of the immune system and circadian function. In addition, VPAC receptors have been shown to function in vitro to modulate the infection of HIV by a signal transduction pathway that appears to regulate viral integration. In this article, the affects of VPAC stimulation on HIV infection will be reviewed and approaches for the development of HIV/AIDS therapeutics that target these receptors will be described. Novel HIV/AIDS therapeutics are urgently required to stem the continued spread of this disease, particularly in underdeveloped countries. Drug design to inhibit signaling through VPAC1 and stimulate signaling through VPAC2 could lead to alternative therapies for the treatment and/or prevention of HIV/AIDS.
Keywords: neuropeptide receptors; HIV/AIDS; VPAC1; VPAC2; HIV therapeutics neuropeptide receptors; HIV/AIDS; VPAC1; VPAC2; HIV therapeutics
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Branch, D.R. Neuropeptide Receptors: Novel Targets for HIV/AIDS Therapeutics. Pharmaceuticals 2011, 4, 485-493.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert